Skip to main content

Table 2 ETS, DpR and outcomes according to the primary tumor location in three RCTs

From: Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis

Characteristic

PRIME

FIRE-3

PEAK

Left-sided

Right-sided

Left-sided

Right-sided

Left-sided

Right-sided

Pani + FOLFOX4

(n = 169)

FOLFOX

(n = 159)

Pani + FOLFOX4

(n = 39)

FOLFOX

(n = 49)

Cet + FOLFIRI

(n = 124)

Bev + FOLFIRI

(n = 133)

Cet + FOLFIRI

(n = 30)

Bev + FOLFIRI

(n = 38)

Pani+mFOLFOX6

(n = 53)

Bev + mFOLFOX6

(n = 54)

Pani+mFOLFOX6

(n = 22)

Bev + mFOLFOX6

(n = 14)

ETS,n (%)

104 (62)

57 (36)

12 (31)

15 (31)

88 (71)

67 (50.4)

17 (56.7)

16 (42.1)

31 (58)

22 (41)

12 (55)

3 (21)

Median PFS (95% CI), months

14.8 (12.5–18.5)

11.1 (9.3–13.9)

14.9 (7.4–27.2)

7.3 (5.6–11.1)

NR

NR

7.8 (2.1–20.5)

13.4 (3.8–21.2)

16.2 (13.0–20.3)

12.9 (9.3–18.6)

10.8 (5.5–15.8)

18.4 (16.6–21.4)

HR (95%CI) 1.718 (0.832, 3.545) P = 0.137

Median OS (95% CI), months

35.0 (29.8–41.9)

31.7 (23.8–38.1)

27.2 (8.0–57.4)

23.6 (7.2–34.5)

NR

NR

27.9 (18.3–37.1)

23.2 (21.0–43.7)

55.4 (41.3–63.0)

48.5 (28.9-NE)

24.6 (10.3–48.4)

26.2 (21.0–31.3)

HR (95%CI) 1.054 (0.453, 2.453) P = 0.903

No. of ETS,n (%)

49 (29)

87 (55)

22 (56)

27 (55)

36 (29)

66 (49.6)

13 (43.3)

22 (57.9)

20 (38)

28 (52)

7 (32)

9 (64)

Median PFS (95% CI), months

9.4 (5.8–13.8)

6.9 (5.5–7.8)

6.5 (4.0–9.9)

6.9 (3.6–11.9)

NR

NR

2.8 (1.8–5.8)

5.2 (3.1–8.6)

11.6 (7.5–16.4)

12.4 (7.4–13.0)

5.8 (3.6–9.8)

12.6 (1.8–13.8)

HR (95%CI)1.743 (0.841,3.609) P = 0.129

Median OS (95% CI), months

19.9 (13.5–27.5)

17.2 (14.2–20.7)

10.6 (6.1–22.5)

13.1 (6.1–18.8)

NR

NR

11.7 (5.9–18.9)

15.9 (13.0–24.0)

34.2 (17.3–48.0)

27.7 (21.0–32.0)

15.3 (5.8–46.1)

23.3 (6.0–29.0)

HR (95%CI) 1.902 (0.892, 4.056) P = 0.0902

Median DpR %

59

49

37

50

42

30.8

25.8

17.7

70

48

50

45

Any resection, n (%)

25 (15)

21 (13)

4 (10)

6 (12)

NR

NR

NR

NR

9 (17)

10 (19)

2 (9)

1 (7)

R0 resection, n (%)

19 (11)

16 (10)

2 (5)

1 (2)

NR

NR

NR

NR

7 (13)

6 (11)

1 (5)

1 (7)

  1. ETS status was unknown for some patients only FIRE-3 reported the HR for PFS and OS
  2. NR not reported, NE not evaluable, cet cetuximab, pani panitumumab, bev bevacizumab
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us